Journal
EUROPEAN JOURNAL OF NEUROLOGY
Volume 15, Issue 10, Pages 1135-1139Publisher
WILEY
DOI: 10.1111/j.1468-1331.2008.02256.x
Keywords
A beta 42/40 ratio; early-onset dementia; genetics; language impairment; novel mutation; presenilin 2
Categories
Funding
- Research Council at Copenhagen University Hospital Rigshospitalet
- Danish Alzheimer Research Foundation
- Novo Nordisk Foundation
Ask authors/readers for more resources
Background: Mutations in the Presenilin 2 gene (PSEN2) are rare causes of Alzheimer's disease (AD). Pathogenic mutations in the genes associated with autosomal dominant inherited AD have been shown to alter processing of the amyloid precursor protein (APP) resulting in a relative increase of the amount of A beta 42 peptide. Methods and results: We present a patient with neuropathologically confirmed early-onset AD characterized by profound language impairment. The patient was heterozygous for a novel missense mutation in exon 11 of the PSEN2 gene leading to a predicted amino acid substitution from valine to methionine in position 393, a conserved residue. However, in vitro expression of PSEN2 V393M cDNA did not result in detectable increase of the secreted A beta 42/40 peptide ratio. The mutation was not found in 384 control individuals tested. Conclusions: The possible pathogenic nature of the mutation is not clarified. We discuss the limitations of functional PSEN2 studies and the challenges associated with genetic counselling of family members at risk.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available